Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Gilead 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Gilead 1Q

Product sales were up 27% to a record $1.5 billion driven by the antiviral franchise, with sales up 28% to $1.3 billion.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Gilead 1Q

1Q Revenues: $1.5 billion (+22%)

1Q Earnings: $589.1 million (+21%)

Comments: Product sales were up 27% to a record $1.5 billion driven by the antiviral franchise, with sales up 28% to $1.3 billion. Truvada sales increased 23% to $590.4 million; Atripla sales were up 57% to $509.9 million; other antiviral product sales, including Viread, Hepsera, and Emtriva, were $240.6 million (-1%). Sales of Letairis for the treatment of pulmonary arterial hypertension were up 95% to $39.6 million. Royalty, contract and other revenues were $82.9 million (-29%). This decrease was driven primarily by lower Tamiflu sales.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters